cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.21227/0t39-0a50
title: Indonesian Marketplace Product

description: This is dataset from shopee, bukalapak, and tokopedia which is used to classify whether a seller is a drop shipper or not.
DOI: 10.5281/zenodo.5905349
title: Dataset of Functionally Equivalent Java Methods

description: This is a dataset of functionally equivalent Java methods. This dataset is published as a supplemental data as the following submission. Yoshiki Higo, Shinsuke Matsumoto, Shinji Kusumoto, and Kazuya Yasuda, "Constructing Dataset of Functionally Equivalent Java Methods Using Automated Test Generation Techniques", submitted to MSR 2022. This dataset includes 276 groups of functionally equivalent Java methods, which have been manually verified by the authors. The 276 groups include 728 Java methods in total.
DOI: 10.25345/c5mk33
title: MassIVE MSV000088732 - LC-MS/MS DDA Method Optimization Natural Products
title: Untargeted-metabolomics LC-MS/MS analysis of commercial natural products pool, analyzed with different DDA settings with the objective to find the best one.
DOI: 10.6084/m9.figshare.19069711.v1
title: Additional file 2 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 2: Table S3. Differentially expressed host genes identified in the malignant tissue samples having high vs. low Shewanella counts.
DOI: 10.6084/m9.figshare.19069714
title: Additional file 3 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 3: Table S4. Differentially expressed host genes identified in the malignant tissue samples having low vs. high Vibrio parahaemolyticus and Staphylococcus saprophyticus counts, respectively.
DOI: 10.6084/m9.figshare.19069711
title: Additional file 2 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 2: Table S3. Differentially expressed host genes identified in the malignant tissue samples having high vs. low Shewanella counts.
DOI: 10.6084/m9.figshare.19069714.v1
title: Additional file 3 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 3: Table S4. Differentially expressed host genes identified in the malignant tissue samples having low vs. high Vibrio parahaemolyticus and Staphylococcus saprophyticus counts, respectively.
DOI: 10.6084/m9.figshare.19069717
title: Additional file 4 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 4: Table S6. Normalised microbial count data for the discovery cohort.
DOI: 10.6084/m9.figshare.19069717.v1
title: Additional file 4 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 4: Table S6. Normalised microbial count data for the discovery cohort.
DOI: 10.6084/m9.figshare.19069720
title: Additional file 5 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 5: Table S7. Normalised microbial count data for the validation cohort.
DOI: 10.6084/m9.figshare.19069723
title: Additional file 6 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 6: Table S8. Normalised host gene count data for the discovery cohort - benign samples.
DOI: 10.6084/m9.figshare.19069720.v1
title: Additional file 5 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 5: Table S7. Normalised microbial count data for the validation cohort.
DOI: 10.6084/m9.figshare.19069723.v1
title: Additional file 6 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 6: Table S8. Normalised host gene count data for the discovery cohort - benign samples.
DOI: 10.6084/m9.figshare.19069726.v1
title: Additional file 7 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 7: Table S9. Normalised host gene count data for the discovery cohort - malignant samples 1-42.
DOI: 10.6084/m9.figshare.19069729
title: Additional file 8 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 8: Table S10. Normalised host gene count data for the discovery cohort - malignant samples 43-83.
DOI: 10.6084/m9.figshare.19069726
title: Additional file 7 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 7: Table S9. Normalised host gene count data for the discovery cohort - malignant samples 1-42.
DOI: 10.6084/m9.figshare.19069729.v1
title: Additional file 8 of Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

description: Additional file 8: Table S10. Normalised host gene count data for the discovery cohort - malignant samples 43-83.
DOI: 10.6084/m9.figshare.19069744.v1
title: Additional file 2 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 2: Supplementary Table 1. Enriched GO terms and genes in MD1. Supplementary Table 2. Enriched GO terms and genes in MD5. Supplementary Table 3. Enriched GO terms and genes in MD6.
DOI: 10.6084/m9.figshare.19069747
title: Additional file 3 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 3: Supplementary data 1. Input data of CLANS (GPCR Family 1).
DOI: 10.6084/m9.figshare.19069747.v1
title: Additional file 3 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 3: Supplementary data 1. Input data of CLANS (GPCR Family 1).
DOI: 10.6084/m9.figshare.19069744
title: Additional file 2 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 2: Supplementary Table 1. Enriched GO terms and genes in MD1. Supplementary Table 2. Enriched GO terms and genes in MD5. Supplementary Table 3. Enriched GO terms and genes in MD6.
DOI: 10.6084/m9.figshare.19069750
title: Additional file 4 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 4: Supplementary data 2. Input data of CLANS (GPCR Family 2).
DOI: 10.6084/m9.figshare.19069753
title: Additional file 5 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 5: Supplementary data 3. Input data of CLANS (GPCR Family 3).
DOI: 10.6084/m9.figshare.19069753.v1
title: Additional file 5 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 5: Supplementary data 3. Input data of CLANS (GPCR Family 3).
DOI: 10.6084/m9.figshare.19069756.v1
title: Additional file 6 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 6: Supplementary data 4. Input data of CLANS (GPCR others).
DOI: 10.6084/m9.figshare.19069750.v1
title: Additional file 4 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 4: Supplementary data 2. Input data of CLANS (GPCR Family 2).
DOI: 10.6084/m9.figshare.19069756
title: Additional file 6 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 6: Supplementary data 4. Input data of CLANS (GPCR others).
DOI: 10.6084/m9.figshare.19069759
title: Additional file 7 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 7: Supplementary material 1. R script for calculating z scores.
DOI: 10.6084/m9.figshare.19069759.v1
title: Additional file 7 of Gene expression alterations from reversible to irreversible stages during coral metamorphosis

description: Additional file 7: Supplementary material 1. R script for calculating z scores.
DOI: 10.6084/m9.figshare.19069758
title: Additional file 10 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 10. Expression data of circRNA in cohort 1.
DOI: 10.6084/m9.figshare.19069758.v1
title: Additional file 10 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 10. Expression data of circRNA in cohort 1.
DOI: 10.6084/m9.figshare.19069761.v1
title: Additional file 11 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 11. Expression data of circRNA in cohort 2.
DOI: 10.6084/m9.figshare.19069761
title: Additional file 11 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 11. Expression data of circRNA in cohort 2.
DOI: 10.6084/m9.figshare.19069764
title: Additional file 12 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 12. Expression data of circRNA in cohort 3.
DOI: 10.6084/m9.figshare.19069764.v1
title: Additional file 12 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 12. Expression data of circRNA in cohort 3.
DOI: 10.6084/m9.figshare.19069767.v1
title: Additional file 13 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 13. Expression data of circRNA in cohort 4.
DOI: 10.6084/m9.figshare.19069767
title: Additional file 13 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 13. Expression data of circRNA in cohort 4.
DOI: 10.6084/m9.figshare.19069776.v1
title: Additional file 3 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 3. circRNA top biomarker candidates selected for validation.
DOI: 10.6084/m9.figshare.19069785
title: Additional file 5 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 5. Association of abundant circRNAs to clinicopathological parameters in RP cohort 1.
DOI: 10.6084/m9.figshare.19069785.v1
title: Additional file 5 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 5. Association of abundant circRNAs to clinicopathological parameters in RP cohort 1.
DOI: 10.6084/m9.figshare.19069788
title: Additional file 6 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 6. Validation of dysregulated circRNA top candidates.
DOI: 10.6084/m9.figshare.19069788.v1
title: Additional file 6 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 6. Validation of dysregulated circRNA top candidates.
DOI: 10.6084/m9.figshare.19069779
title: Additional file 4 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 4. Dysregulated circRNAs in cohort 1.
DOI: 10.6084/m9.figshare.19069779.v1
title: Additional file 4 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 4. Dysregulated circRNAs in cohort 1.
DOI: 10.6084/m9.figshare.19069791.v1
title: Additional file 7 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 7. Validation of circRNA candidates associated with clinicopathological parameters.
DOI: 10.6084/m9.figshare.19069776
title: Additional file 3 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 3. circRNA top biomarker candidates selected for validation.
DOI: 10.6084/m9.figshare.19069791
title: Additional file 7 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 7. Validation of circRNA candidates associated with clinicopathological parameters.
DOI: 10.6084/m9.figshare.19069797
title: Additional file 9 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 9. Detectability of circRNA top candidates in EV-enriched plasma samples.
DOI: 10.6084/m9.figshare.19069797.v1
title: Additional file 9 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 9. Detectability of circRNA top candidates in EV-enriched plasma samples.
DOI: 10.6084/m9.figshare.19069794
title: Additional file 8 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 8. Uni- and multivariate Cox regression analyses of biochemical recurrence-free survival time in RP cohorts 1 and 3.
DOI: 10.6084/m9.figshare.19069794.v1
title: Additional file 8 of The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

description: Additional file 8. Uni- and multivariate Cox regression analyses of biochemical recurrence-free survival time in RP cohorts 1 and 3.
DOI: 10.6084/m9.figshare.19069860
title: Additional file 1 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 1: Metadata collected or available for takahē faecal samples analysed in this study.
DOI: 10.6084/m9.figshare.19069860.v1
title: Additional file 1 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 1: Metadata collected or available for takahē faecal samples analysed in this study.
DOI: 10.6084/m9.figshare.19069863
title: Additional file 2 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 2: Taxonomic assignments of amplicon sequence variants (ASVs) obtained from takahē faecal samples.
DOI: 10.6084/m9.figshare.19069863.v1
title: Additional file 2 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 2: Taxonomic assignments of amplicon sequence variants (ASVs) obtained from takahē faecal samples.
DOI: 10.6084/m9.figshare.19069866
title: Additional file 3 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 3: Non-rarefied ASV table.
DOI: 10.6084/m9.figshare.19069869
title: Additional file 4 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 4: R markdown file used for statistical analyses of ASV data.
DOI: 10.6084/m9.figshare.19069866.v1
title: Additional file 3 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 3: Non-rarefied ASV table.
DOI: 10.6084/m9.figshare.19069869.v1
title: Additional file 4 of Gut microbiota of the threatened takahē: biogeographic patterns and conservation implications

description: Additional file 4: R markdown file used for statistical analyses of ASV data.
DOI: 10.6084/m9.figshare.19069891
title: Additional file 2 of Barriers and facilitators to person-centred infection prevention and control: results of a survey about the Dementia Isolation Toolkit

description: Additional file 2.
DOI: 10.6084/m9.figshare.19069891.v1
title: Additional file 2 of Barriers and facilitators to person-centred infection prevention and control: results of a survey about the Dementia Isolation Toolkit

description: Additional file 2.
DOI: 10.48370/ofd/qwdlja
title: Nemania serpens (Pers.) Gray., 2884

description: Fungarium Makromycetes
DOI: 10.48370/ofd/e2isri
title: Nemania serpens (Pers.) Gray., 2926

description: Fungarium Makromycetes
DOI: 10.15129/cbbe122f-4ee1-4bfb-9ec7-46c664bf10f2
title: Data for: "Cobalt neurotoxicity: transcriptional effect of elevated cobalt blood levels in the rodent brain"

description: The data belongs to the publication: “Cobalt neurotoxicity: transcriptional effect of elevated cobalt blood levels in the rodent brain” The files of this dataset can be opened with Microsoft Excel. The metal content data was generated with the Agilent 7700× octopole collision ICP-MS system, the RNA-sequencing analysis was performed through the BGISEQ-500 sequencing platform, and the RT-qPCR data was obtained through the StepOnePlus Real-Time PCR system. The publication and the README file included in this dataset provide detailed information about the files included.
DOI: 10.48479/fyst-hj47
title: The 1.28 GHz MeerKAT Galactic Center Mosaic

description: The mosaic has been formed from the innermost 20 pointings of the MeerKAT Galactic centre survey, totalling 144 hours of integration time. The data have been consistently processed to deliver an angular resolution of 4" over 6.5 square degrees. A lower (8") angular resolution spectral index mosaic and associated error map are also provided.
DOI: 10.6084/m9.figshare.17372633
title: Supplementary Material for: Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-line Sorafenib in Randomized Controlled Trials

description: Background: Sorafenib has consistently served as the control arm in multiple RCTs evaluating novel therapies for advanced HCC for more than a decade. Analyzing trends in clinical outcomes of patients treated with sorafenib for the same indication over time offers the opportunity for unique insight into the evolution of clinical trial conduct and potential non-drug factors impacting outcomes. Methods: We identified RCTs in patients with treatment-naïve advanced HCC where sorafenib was compared to another systemic therapy or placebo. We extracted trial-level demographic, clinicopathologic, and outcome data (OS, progression-free survival (PFS), objective response rate (ORR) and duration of therapy). Sample-weighted linear regression was used to identify temporal trends with significance set at p0.05. Results: Sixteen RCTs (9 phase III and 7 phase II) enrolling 4086 patients treated with sorafenib were included in the analysis. Included trials enrolled patients from 2005-2019. OS has significantly improved by 4.5 months from 2005-2019 (p=0.048) over time. Thirteen studies provided data on PFS using RECIST 1.1, with no significant change over time (p=0.69). ORR assessed by RECIST 1.1 has significantly improved by 6.0% over time (p=0.003). Median duration of therapy with sorafenib has decreased by 53% since the enrollment of the first clinical trial in 2005, from 23.1 weeks to 12.2 weeks (p=0.0037). There was no significant change in patient demographics were identified over time to explain the OS findings. Conclusion: The median OS of patients with advanced HCC treated with sorafenib has improved significantly over 15 years. At the same time, the median duration of therapy with sorafenib has decreased. The reason for these findings was not explained by changing demographics of patients enrolled in these trials and has implications for ongoing clinical trials.
DOI: 10.6084/m9.figshare.17372633.v1
title: Supplementary Material for: Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-line Sorafenib in Randomized Controlled Trials

description: Background: Sorafenib has consistently served as the control arm in multiple RCTs evaluating novel therapies for advanced HCC for more than a decade. Analyzing trends in clinical outcomes of patients treated with sorafenib for the same indication over time offers the opportunity for unique insight into the evolution of clinical trial conduct and potential non-drug factors impacting outcomes. Methods: We identified RCTs in patients with treatment-naïve advanced HCC where sorafenib was compared to another systemic therapy or placebo. We extracted trial-level demographic, clinicopathologic, and outcome data (OS, progression-free survival (PFS), objective response rate (ORR) and duration of therapy). Sample-weighted linear regression was used to identify temporal trends with significance set at p0.05. Results: Sixteen RCTs (9 phase III and 7 phase II) enrolling 4086 patients treated with sorafenib were included in the analysis. Included trials enrolled patients from 2005-2019. OS has significantly improved by 4.5 months from 2005-2019 (p=0.048) over time. Thirteen studies provided data on PFS using RECIST 1.1, with no significant change over time (p=0.69). ORR assessed by RECIST 1.1 has significantly improved by 6.0% over time (p=0.003). Median duration of therapy with sorafenib has decreased by 53% since the enrollment of the first clinical trial in 2005, from 23.1 weeks to 12.2 weeks (p=0.0037). There was no significant change in patient demographics were identified over time to explain the OS findings. Conclusion: The median OS of patients with advanced HCC treated with sorafenib has improved significantly over 15 years. At the same time, the median duration of therapy with sorafenib has decreased. The reason for these findings was not explained by changing demographics of patients enrolled in these trials and has implications for ongoing clinical trials.
DOI: 10.6084/m9.figshare.19069974.v1
title: Additional file 4 of Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda

description: Additional file 4: A tabular presentation of data used to determine the weights to consider when adjusting sampled facilities to match the population distribution of facilities. For the final analysis weights presented in Table 1 were considered.
DOI: 10.6084/m9.figshare.19069974
title: Additional file 4 of Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda

description: Additional file 4: A tabular presentation of data used to determine the weights to consider when adjusting sampled facilities to match the population distribution of facilities. For the final analysis weights presented in Table 1 were considered.
DOI: 10.6084/m9.figshare.19069983
title: Additional file 7 of Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda

description: Additional file 7: A tabular presentation of how facilities were sampled, enrolled, replaced (new) or excluded arriving at the total number of facilities included in the final analysis by district, overall and stratified by facility type (level and owner).
DOI: 10.6084/m9.figshare.19069983.v1
title: Additional file 7 of Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda

description: Additional file 7: A tabular presentation of how facilities were sampled, enrolled, replaced (new) or excluded arriving at the total number of facilities included in the final analysis by district, overall and stratified by facility type (level and owner).
DOI: 10.6084/m9.figshare.19070007
title: Additional file 4 of Video-based long-term follow up of musician’s dystonia in pianists reveals similar improvements following different treatment strategies: a retrospective observational study

description: Additional file 4. Informative priors placed on parameter estimates for model m4airr (see Additional file 6).
DOI: 10.6084/m9.figshare.19070007.v1
title: Additional file 4 of Video-based long-term follow up of musician’s dystonia in pianists reveals similar improvements following different treatment strategies: a retrospective observational study

description: Additional file 4. Informative priors placed on parameter estimates for model m4airr (see Additional file 6).